Skip to main content
. Author manuscript; available in PMC: 2017 Apr 25.
Published in final edited form as: Gene Ther. 2016 Oct 25;24(1):21–30. doi: 10.1038/gt.2016.70

Figure 4. Checkpoint inhibition improves VSV-ASMEL therapy and uncovers a Th1 anti-tumor response.

Figure 4

C57Bl/6 mice (7–8 per group) bearing 5 day established B16 tumors, received 6 injections of either VSV-GFP or VSV-ASMEL on days 5,7,9,12,14,16, followed by 6 injections of anti-PD-1 (250 μg) or control Ig on days 19,21,23,26,28,30. A. Tumor measurements were taken 3x per week and mice euthanised when tumors reached 1.0 cm diameter. Graph shown is representative of n=3 individual experiments, *p<0.05 Log-Rank test. B&C. S/LN were harvested from 4 mice/group at time of sacrifice. Single cell suspension cultures of S/LN were re-stimulated with B16 F/T lysate every 24 h. Supernatants were harvested after 72 h and tested for IL-17 (B) and IFN-γ (C) by ELISA. Bars on graphs show values +SD (triplicate wells) for individual mice. **p<0.01, ***p<0.001 two-tailed t-test.